US Stock Insider Trading | Biodesix disclosed 5 insider transactions on February 23

K-LinePoet · 2026-02-26T08:55:27+00:00

On February 23, 2026, Biodesix disclosed multiple insider transactions, with Director Hutton Scott and several executives selling a total of approximately $25,600 worth of stock on that day. The company focuses on developing diagnostic solutions for lung diseases using AI platforms.

K-LinePoet

2026-02-26 08:55:27

Abstract generation in progress

On February 23, 2026, Biodesix (BDSX) disclosed five insider trades. Director Hutton Scott sold 1,490 shares on that date.

[Recent Insider Trades]

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 23, 2026	Director	Hutton Scott	February 23, 2026	Sell	1,490	12.78	$19,000
February 23, 2026	Executive	Cowie Robin Harper	February 23, 2026	Sell	535	12.78	$6,834.95
February 23, 2026	Executive	Pestano Gary Anthony	February 23, 2026	Sell	556	12.78	$7,103.23
February 23, 2026	Executive	O’Kane Kieran	February 23, 2026	Sell	535	12.78	$6,834.95
February 23, 2026	Executive	Vazquez Chris	February 23, 2026	Sell	211	12.78	$2,695.65
February 11, 2026	Executive	Pestano Gary Anthony	February 10, 2026	Sell	540	10.08	$5,445.41
February 11, 2026	Executive	Vazquez Chris	February 10, 2026	Sell	101	10.08	$1,018.49
February 11, 2026	Director	Hutton Scott	February 10, 2026	Sell	3,559	10.08	$35,900
February 11, 2026	Executive	Cowie Robin Harper	February 10, 2026	Sell	941	10.08	$9,489.14
February 11, 2026	Executive	O’Kane Kieran	February 10, 2026	Sell	584	10.08	$5,889.11

[Company Information]

Biodesix, Inc. was founded in Delaware in 2005. The company is a leading data-driven diagnostic solutions provider that leverages its proprietary AI platform and advanced technology to discover, develop, and commercialize solutions addressing unmet clinical needs, primarily focusing on lung diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.